Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P130018/S004

ProACT Adjustable Continence Therapy for Men

Uromedica, Inc. · Decision date Oct 3, 2025

FDA DECISIONP130018/S004

What did the FDA approve?

FDA records P130018/S004 as a supplement to PMA P130018, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Oct 3, 2025.

FDA approval order statement

Approval of the modifications to the study protocol including expansion of the study to 10-14 study sites and modifications to the Informed Consent Form for the post-approval study.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Gastroenterology, Urology
Decision date
Oct 3, 2025
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P130018/S004
Regulatory pathway
PMA supplement
Product code
EZY
Decision code
APPR
Decision date
Oct 3, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Device, incontinence, mechanical/hydraulic.

Product code
EZY
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P130018/S004 received

    Application receipt date recorded by FDA.

  2. P130018/S004 · FDA decision

    Normal 180 Day Track No User Fee

  3. P130018/S005 · Related supplement

    ProACT Adjustable Continence Therapy for Men

  4. P130018/S006 · Related supplement

    ProACT Adjustable Continence Therapy for Men

Timeline entries are records held by MedtechLedger for P130018. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P130018

Product / regulatory recordCompanyPathwayDecision dateSource
Uromedica, Inc.PMA supplementJan 28, 2026FDA
Uromedica, Inc.PMA supplementFeb 11, 2026FDA

Explore the linked device profile

Other records with product code EZY

Product / regulatory recordCompanyPathwayDecision dateSource
Boston Scientific CorpPMA supplementSep 14, 2026FDA
Boston Scientific CorpPMA supplementFeb 25, 2026FDA
Boston Scientific CorpPMA approvalJun 14, 2001FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Uromedica, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1840 Berkshire Ln. N., Plymouth, MN, 55441

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records